Skip to main content
S&P 5007,722.60+0.60%DOW52,377.57+0.03%NASDAQ26,477.81+1.18%BTC$80,652.00+0.63%ETH$2,343.36+0.75%GOLD$4,075.00+0.01%OIL$100.37+0.47%
Smart Investors Daily
SID Premium
CL

NASDAQ · CLNN

Clene Inc.

Healthcare · Biotechnology

$3.97

Up+$0.13 (+3.39%)

Updated Oct 28, 2026, 9:17 AM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
64.85M
P/E ratio
-2.23
Dividend yield
0.00%
52-week range
$3.02 – $8.67
Volume
31.31K
Avg. volume
192.2K

Price performance · CLNN

CLNN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 27, 2026

CLNN closed at $3.97 after 21 trading sessions, down 3.17% for the selected period.

Last close
$3.97
Period change
-3.17%
Period low
$3.10
Period high
$4.10
Daily close
View OHLC price history
CLNN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 27, 2026$3.84$3.99$3.84$3.9731.31K
Oct 26, 2026$3.92$3.92$3.78$3.8433.86K
Oct 23, 2026$3.79$3.9699$3.77$3.8821.4K
Oct 22, 2026$3.73$4.01$3.63$3.88124.25K
Oct 21, 2026$3.76$4.00$3.71$3.7684.56K
Oct 20, 2026$3.52$4.0499$3.1959$3.73202.01K
Oct 19, 2026$3.30$3.3908$3.10$3.2988.49K
Oct 16, 2026$3.39$3.39$3.0152$3.10204.44K
Oct 15, 2026$3.25$3.439$3.20$3.305134.07K
Oct 14, 2026$3.38$3.40$3.235$3.3171.55K
Oct 13, 2026$3.69$3.695$3.36$3.39114.66K
Oct 12, 2026$3.93$3.93$3.6708$3.6874K
Oct 9, 2026$3.83$3.955$3.80$3.8648.13K
Oct 8, 2026$3.94$3.9592$3.77$3.8882.33K
Oct 7, 2026$3.85$4.01$3.71$3.9240.9K
Oct 6, 2026$3.92$4.04$3.80$3.8744.98K
Oct 5, 2026$4.09$4.11$3.80$3.91278.24K
Oct 2, 2026$4.08$4.17$3.97$4.0861.48K
Oct 1, 2026$4.10$4.1503$4.00$4.02100.03K
Sep 30, 2026$4.14$4.3269$4.01$4.0852.01K
Sep 29, 2026$4.10$4.2585$4.0601$4.1070.38K

Latest CLNN news

The latest Smart Investors Daily articles mentioning CLNN.

Stock researchCompany · Overview

CLNN research

Overview

Company profile and research snapshot.

Company profile

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$50.00
Implied upside
—
Analysts
—
CLNN recent ratings
DateFirmRatingTarget
Oct 19, 2026HC Wainwright & Co.Buy—
May 4, 2026HC Wainwright & Co.Buy—
May 4, 2026D. Boral CapitalBuy—
Mar 13, 2026Canaccord GenuityBuy—
Mar 12, 2026D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 19, 2026

Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS

NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of neurodegenerative diseases, announced that it has submitted a New Drug Application (NDA) earlier in October to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of CNM-Au8® for the treatment o

Yahoo · Oct 2, 2026

Clene Targets Q4 FDA Filing for ALS Drug CNM-Au8, Eyes Mid-2027 Decision

Clene (NASDAQ:CLNN) said it plans to submit a new drug application to the U.S. Food and Drug Administration at the beginning of the fourth quarter for CNM-Au8, its investigational treatment for amyotrophic lateral sclerosis, or ALS. In a fireside chat at the Lytham Partners Fall 2026 Investor Confe

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By